Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Protective B-cell epitopes of Francisella tularensis O-polysaccharide in a mouse model of respiratory tularaemia.

Lu Z, Madico G, Roche MI, Wang Q, Hui JH, Perkins HM, Zaia J, Costello CE, Sharon J.

Immunology. 2012 Jul;136(3):352-60. doi: 10.1111/j.1365-2567.2012.03589.x.

2.

The binding sites of monoclonal antibodies to the non-reducing end of Francisella tularensis O-antigen accommodate mainly the terminal saccharide.

Lu Z, Rynkiewicz MJ, Yang CY, Madico G, Perkins HM, Wang Q, Costello CE, Zaia J, Seaton BA, Sharon J.

Immunology. 2013 Nov;140(3):374-89. doi: 10.1111/imm.12150.

3.

Antibodies to both terminal and internal B-cell epitopes of Francisella tularensis O-polysaccharide produced by patients with tularemia.

Lu Z, Perkins HM, Sharon J.

Clin Vaccine Immunol. 2014 Feb;21(2):227-33. doi: 10.1128/CVI.00626-13. Epub 2013 Dec 18.

4.

Functional and structural characterization of Francisella tularensis O-antigen antibodies at the low end of antigen reactivity.

Lu Z, Rynkiewicz MJ, Yang CY, Madico G, Perkins HM, Roche MI, Seaton BA, Sharon J.

Monoclon Antib Immunodiagn Immunother. 2014 Aug;33(4):235-45. doi: 10.1089/mab.2014.0022.

5.

An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.

Bakshi CS, Malik M, Mahawar M, Kirimanjeswara GS, Hazlett KR, Palmer LE, Furie MB, Singh R, Melendez JA, Sellati TJ, Metzger DW.

Vaccine. 2008 Sep 26;26(41):5276-88. doi: 10.1016/j.vaccine.2008.07.051. Epub 2008 Aug 8.

6.

Genetic modification of the O-polysaccharide of Francisella tularensis results in an avirulent live attenuated vaccine.

Kim TH, Pinkham JT, Heninger SJ, Chalabaev S, Kasper DL.

J Infect Dis. 2012 Apr 1;205(7):1056-65. doi: 10.1093/infdis/jir620. Epub 2011 Oct 3.

7.

Attenuation and protective efficacy of an O-antigen-deficient mutant of Francisella tularensis LVS.

Li J, Ryder C, Mandal M, Ahmed F, Azadi P, Snyder DS, Pechous RD, Zahrt T, Inzana TJ.

Microbiology. 2007 Sep;153(Pt 9):3141-53.

PMID:
17768257
8.

Characterization of monoclonal antibodies to terminal and internal O-antigen epitopes of Francisella tularensis lipopolysaccharide.

Roche MI, Lu Z, Hui JH, Sharon J.

Hybridoma (Larchmt). 2011 Feb;30(1):19-28. doi: 10.1089/hyb.2010.0083.

9.

A ΔclpB mutant of Francisella tularensis subspecies holarctica strain, FSC200, is a more effective live vaccine than F. tularensis LVS in a mouse respiratory challenge model of tularemia.

Golovliov I, Twine SM, Shen H, Sjostedt A, Conlan W.

PLoS One. 2013 Nov 13;8(11):e78671. doi: 10.1371/journal.pone.0078671. eCollection 2013.

10.

Generation and characterization of hybridoma antibodies for immunotherapy of tularemia.

Lu Z, Roche MI, Hui JH, Unal B, Felgner PL, Gulati S, Madico G, Sharon J.

Immunol Lett. 2007 Oct 15;112(2):92-103. Epub 2007 Aug 8.

11.

A defined O-antigen polysaccharide mutant of Francisella tularensis live vaccine strain has attenuated virulence while retaining its protective capacity.

Sebastian S, Dillon ST, Lynch JG, Blalock LT, Balon E, Lee KT, Comstock LE, Conlan JW, Rubin EJ, Tzianabos AO, Kasper DL.

Infect Immun. 2007 May;75(5):2591-602. Epub 2007 Feb 12.

13.

Structural analysis of a protective epitope of the Francisella tularensis O-polysaccharide.

Rynkiewicz MJ, Lu Z, Hui JH, Sharon J, Seaton BA.

Biochemistry. 2012 Jul 17;51(28):5684-94. Epub 2012 Jul 2.

14.

Identification of Francisella tularensis outer membrane protein A (FopA) as a protective antigen for tularemia.

Hickey AJ, Hazlett KR, Kirimanjeswara GS, Metzger DW.

Vaccine. 2011 Sep 16;29(40):6941-7. doi: 10.1016/j.vaccine.2011.07.075. Epub 2011 Jul 29.

15.

Specific antibodies protect gamma-irradiated mice against Francisella tularensis infection.

Kubelkova K, Krocova Z, Balonova L, Pejchal J, Stulik J, Macela A.

Microb Pathog. 2012 Nov-Dec;53(5-6):259-68. doi: 10.1016/j.micpath.2012.07.006. Epub 2012 Jul 25.

PMID:
22841607
16.

A typical preparation of Francisella tularensis O-antigen yields a mixture of three types of saccharides.

Wang Q, Shi X, Leymarie N, Madico G, Sharon J, Costello CE, Zaia J.

Biochemistry. 2011 Dec 20;50(50):10941-50. doi: 10.1021/bi201450v. Epub 2011 Nov 28.

17.

Intranasal vaccination induces protective immunity against intranasal infection with virulent Francisella tularensis biovar A.

Wu TH, Hutt JA, Garrison KA, Berliba LS, Zhou Y, Lyons CR.

Infect Immun. 2005 May;73(5):2644-54.

20.

[Species- and genus-specific antigenic epitopes of Francisella tularensis lipopolysaccharides].

Pavlovich NV, Aronova NV, Onoprienko NN, Sorokin VM, Mazrukho BL.

Mol Gen Mikrobiol Virusol. 2000;(3):7-12. Russian.

PMID:
10975073
Items per page

Supplemental Content

Write to the Help Desk